Ucal (UCAL)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Price-to-book of 0.66 offers a 34% discount to stated book value of ₹160.59 per share.
• Promoter holding of 70.28% indicates strong alignment with minority shareholders.
• Market cap of ₹240 Cr versus latest quarter sales of ₹199 Cr suggests meaningful operating scale at a low sales multiple.
• Debt/equity of 0.87, while notable, does not signal immediate distress.

Concerns

• Net loss of ₹10 Cr in the latest quarter and profit growth of -212.5% make the P/E meaningless and show ongoing losses.
• ROE of 0.39% and ROCE of 0.90% reflect very poor returns on capital and weak competitive positioning.
• Sales growth of -2.35% and a Piotroski F-score of 3/9 point to deteriorating fundamentals.
• No dividend yield means shareholders are wholly dependent on a future recovery that may not materialise.

AI Analysis

Ucal is the kind of stock that tests a value investor's discipline. On the surface, ₹105.83 versus book value of ₹160.59 looks cheap—a price-to-book of 0.66, about a 34% margin of safety. But Graham warned that discounting assets is only worthwhile if assets can earn a return. Here, ROE is 0.39% and ROCE is 0.90%; essentially, the business earns almost nothing on shareholders' money. The latest quarter sums up the problem: sales of ₹199 Cr but a net loss of ₹10 Cr, while profit growth collapsed by 212.5%. Sales growth is negative at -2.35%. A Piotroski score of 3/9 suggests poor financial health, not latent quality. Debt/equity at 0.87 is manageable for a going concern, but with no dividend and negative profits, the road to compounding is unclear. I notice promoter holding is 70.28%, which is good—owners have real skin in the game. Yet even the best owners cannot quickly fix weak demand and low pricing power in auto components. Is there a moat? The numbers don't show one; this appears to be a commodity-like business competing on cost and capacity. The market cap of ₹240 Cr looks cheap against book value, but fair value is hostage to a turnaround, and turnarounds often don't happen. Would I buy the whole company at this price? Only if I believed book value would stop shrinking and ROE could move toward double digits. That is not visible in these numbers. So I will watch, not chase. The discount may widen; asset plays need a catalyst. I would rather wait until Ucal shows one or two quarters of genuine operating improvement before deploying capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer